Arthneeti
All Q3 FY25 results →
CB

Concord Biotech

Q3 FY25Pharmaceuticals & Biotechnology

Concord Biotech Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹1,548
Market cap₹16.4K Cr
P/E57.8
Updated26 Aug 2026
Read4 min read

The short version

Concord Biotech targets a 20% to 25% CAGR growth in overall sales/revenue over the next 3 to 5 years. Concord Biotech targets a 20% to 25% CAGR growth in sales over the next 3 to 5 years at the company level.

From Concord Biotech's Q3 FY25 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • Concord Biotech targets a 20% to 25% CAGR growth in overall sales/revenue over the next 3 to 5 years.
  • Growth is expected from both API and formulation segments, with API contributing around 80% and formulations about 20%.
  • API third-party sales are anticipated to grow at around 10-12%, while formulations, especially due to capacity ramp-up, are expected to grow north of 40% to achieve overall 20%+ company growth.
  • Injectables are expected to gradually contribute more, with asset turnovers of INR 300-600 crores and a phased ramp-up over 5 years contributing about 6% growth.
  • Growth is volume-driven with stable pricing; no significant price hikes anticipated.

2 more points from Concord Biotech's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Concord Biotech said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex for FY '24-'25 is largely complete, with INR 225 crores spent on the injectable unit to be capitalized.
  • No significant growth capex expected for FY '24-'25; only maintenance capex of around INR 15-20 crores per annum anticipated.
  • Future capex may be considered if new opportunities arise within or adjacent to fermentation APIs, either in-house or through procurement.
  • Strategic investment: Concord will acquire a 26% equity stake in CleanMax Private Limited and CleanMax Enviro Energy Solutions (renewable energy provider in Gujarat).

2 more points from Concord Biotech's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Concord Biotech said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Concord Biotech has a strong order book position as of Q3 FY '25.
  • Certain opportunities are currently active and anticipated to convert within the quarter.
  • Some customer orders faced delays, pushing certain order executions from Q3 to Q4.
  • There is a possibility, though less likely, that some orders may move beyond Q4 into Q1.
  • The company remains confident in execution based on January and February performance.

2 more points from Concord Biotech's call on order book

Pro opens every point from 15K+ earnings calls

Concord Biotech — Quarterly revenue & net profit

Revenue Net profit
Sep 2024Q2 FY25
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹278 Cr, net profit ₹68 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Concord Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • SMS Pharma. (Q3 FY25)

    Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…

  • Wockhardt Ltd (Q3 FY25)

    725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…

  • Shree Ganesh Rem (Q3 FY25)

    Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…

  • Themis Medicare (Q3 FY25)

    93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Concord Biotech and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Concord Biotech Q3 FY25 results?

Concord Biotech targets a 20% to 25% CAGR growth in overall sales/revenue over the next 3 to 5 years. Concord Biotech targets a 20% to 25% CAGR growth in sales over the next 3 to 5 years at the company level.

What is Concord Biotech share price analysis?

Concord Biotech currently shows a neutral. The stock trades at a P/E of 57.8 with a market cap of ₹16,438 Cr. Investors should review the full earnings analysis for detailed insights.

Is Concord Biotech planning capital expenditure?

Capex for FY '24-'25 is largely complete, with INR 225 crores spent on the injectable unit to be capitalized.

Keep Concord Biotech on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.